GLP-1 receptor agonists have already reshaped diabetes and obesity care. Now, scientists are testing quintuple agonists drugs designed to hit five different metabolic receptors in one shot. Early trials suggest benefits far beyond weight loss, including improved glucose control, NAFLD management, and possibly cardiovascular protection. For India, the implications are unique. With the thin-fat phenotypecentral adiposity at lower BMIs these drugs might deliver outsized benefits compared to Western populations.
But challenges remain: high cost, uncertain safety, and real-world access. If proven safe, quintuple agonists could redefine treatment algorithms. But until affordability and long-term outcomes are clear, endocrinologists will need to balance cutting-edge promise with practical realities of a 100-million strong diabetic population. Would you use or reserve this agonist only for…
